AbbVie is in advanced negotiations to acquire clinical-stage biotechnology company Apogee Therapeutics in an all-cash deal valued at approximately $10.9 billion, according to multiple reports. A formal announcement could be made as soon as Monday, June 22, though neither company has publicly confirmed the talks.